Mounjaro and Psoriasis: Can Tirzepatide Help Inflammatory Skin Conditions?

Psoriasis affects more than 1.8 million adults in the United Kingdom, causing itchy, inflamed plaques that flare unpredictably and often worsen with weight gain. If you are taking Mounjaro (tirzepatide) to lose weight, you may have noticed your skin improving alongside the numbers on the scale. That is not a coincidence.

Emerging clinical evidence now shows that tirzepatide can reduce the systemic inflammation that drives psoriasis, with one landmark trial finding that combining tirzepatide with a standard biologic nearly quintupled the rate of complete skin clearance. In this article, we explain the science behind these findings and what they mean for CutKilo patients living with inflammatory skin conditions.

Yes, there is growing clinical evidence that Mounjaro (tirzepatide) can improve psoriasis, particularly in patients who also carry excess weight. The TOGETHER-PsO trial, published in JAMA Dermatology in May 2026, showed that adding tirzepatide to the biologic ixekizumab raised complete skin clearance rates from 5.8% to 27.1% at 36 weeks. Tirzepatide works by lowering systemic inflammation, reducing visceral fat, and improving the metabolic dysfunction that fuels psoriatic flares.

While Mounjaro is not licensed as a psoriasis treatment, its anti-inflammatory effects are a clinically meaningful bonus for patients who also need to manage their weight.

Psoriasis is not just a skin condition. It is a chronic immune-mediated inflammatory disease driven by overactive T-cells and elevated cytokines, particularly interleukin-17 (IL-17), tumour necrosis factor alpha (TNF-alpha), and interleukin-23 (IL-23). These same inflammatory molecules are produced in large quantities by visceral adipose tissue, the metabolically active fat stored around internal organs.

Obesity and psoriasis share a bidirectional relationship. Excess body fat increases the inflammatory load that triggers and sustains psoriatic plaques. Psoriasis itself, through chronic inflammation and reduced mobility, increases the risk of further weight gain. A 2019 meta-analysis published in the British Journal of Dermatology found that adults with severe psoriasis were 1.8 times more likely to have obesity compared with the general population.

This means that any treatment which reduces visceral fat and lowers systemic inflammation has the potential to improve psoriasis outcomes, even if it was not designed with skin disease in mind.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. While it is primarily prescribed for weight management and type 2 diabetes, its mechanism of action has broad anti-inflammatory effects that extend well beyond appetite suppression.

Data from the SURMOUNT clinical programme show that tirzepatide significantly reduces C-reactive protein (CRP), a key biomarker of systemic inflammation. Patients on the 15 mg dose achieved average CRP reductions of over 50% at 72 weeks. Tirzepatide also lowers circulating levels of IL-6 and TNF-alpha, both of which are directly implicated in the pathogenesis of psoriatic plaques. You can read more about how tirzepatide lowers CRP and inflammatory markers in our detailed guide.

Beyond direct cytokine reduction, tirzepatide shrinks visceral fat depots, which are the primary source of the adipokines that sustain chronic low-grade inflammation. This dual action, reducing both the inflammatory signal and its source, is what makes tirzepatide particularly relevant for conditions like psoriasis.

The strongest evidence for tirzepatide’s role in psoriasis comes from the TOGETHER-PsO trial, a randomised, double-blind study published in JAMA Dermatology in May 2026. The trial enrolled 274 adults with moderate-to-severe plaque psoriasis and a BMI of 27 or above.

Participants were randomised to receive either ixekizumab (a standard IL-17 inhibitor biologic) alone or ixekizumab combined with tirzepatide. At 36 weeks, the results were striking. In the combination group, 27.1% of patients achieved PASI 100, meaning complete clearance of all psoriatic plaques, alongside at least 10% total body weight loss. In the ixekizumab-only group, just 5.8% achieved the same dual outcome.

These findings are significant because they demonstrate that addressing the metabolic component of psoriasis, specifically excess weight and the inflammation it generates, can substantially improve dermatological outcomes. The trial investigators noted that weight loss itself was an independent predictor of skin clearance, reinforcing the clinical rationale for treating both conditions concurrently.

Follow-up studies, including the planned TOGETHER-PsA trial, will examine whether similar benefits extend to psoriatic arthritis, a related condition affecting the joints.

Psoriasis is not the only inflammatory skin condition linked to obesity and systemic inflammation. Hidradenitis suppurativa (HS), a painful condition causing recurrent abscesses in the armpits, groin, and under the breasts, is strongly associated with higher BMI and elevated inflammatory markers. Case reports and small observational studies have described reduced HS flare frequency in patients taking GLP-1 receptor agonists, though larger trials are needed.

Chronic eczema (atopic dermatitis) in adults also has an inflammatory component that can be worsened by obesity. While the evidence is less direct than for psoriasis, the reduction in CRP and pro-inflammatory cytokines seen with tirzepatide may benefit patients with stubborn, treatment-resistant eczema flares. A comprehensive review published in PMC in 2025 highlighted that GLP-1 receptor agonists show anti-inflammatory, wound-healing, and skin-protective properties that warrant further investigation across a range of dermatological conditions.

Because chronic inflammation affects every organ system, including the skin, patients tracking their progress on Mounjaro may benefit from monitoring inflammatory markers alongside body composition. DEXA London, CutKilo’s sister service, offers body composition scans that measure visceral fat directly, giving patients and clinicians an objective way to track whether the metabolic improvements driving skin benefits are being sustained.

If you are a CutKilo patient with psoriasis, your prescribing clinician will assess your skin condition alongside your weight management goals. It is important to understand that Mounjaro is not a replacement for dedicated psoriasis treatments such as topical steroids, phototherapy, or biologic injections. Rather, it can complement them by tackling the underlying metabolic inflammation that makes psoriasis harder to control.

Some patients notice improvements in their skin within the first 8 to 12 weeks of treatment, as CRP levels fall and visceral fat begins to reduce. Others may see changes more gradually over 6 to 12 months. The degree of improvement often correlates with the amount of weight lost and the baseline severity of the skin disease.

Patients experiencing changes in their skin while on Mounjaro should also be aware that rapid weight loss can sometimes cause temporary skin changes, including facial volume loss, which is a separate issue from psoriasis and is discussed in our dedicated guide.

If you have active psoriasis and are considering Mounjaro, let your CutKilo clinician know during your initial consultation so that your treatment plan can be tailored accordingly.

The single most important clinical takeaway is that treating obesity with tirzepatide can meaningfully improve psoriasis by reducing the systemic inflammation and visceral fat that fuel the disease. The TOGETHER-PsO trial provides the strongest evidence to date that combining weight management with conventional psoriasis therapy delivers better skin outcomes than either approach alone. For CutKilo patients with psoriasis, Mounjaro offers the potential for a dual benefit: healthier weight and calmer skin.

Is Mounjaro approved for treating psoriasis? No. Mounjaro (tirzepatide) is licensed for weight management and type 2 diabetes, not psoriasis. However, clinical evidence, including the TOGETHER-PsO trial, shows that the weight loss and anti-inflammatory effects of tirzepatide can improve psoriasis outcomes when used alongside standard dermatological treatments.

How quickly will I see psoriasis improvements on Mounjaro? Some patients report improvements in skin inflammation within 8 to 12 weeks, as systemic CRP levels fall and visceral fat begins to reduce. For others, meaningful skin changes may take 6 to 12 months, depending on the severity of the psoriasis and the amount of weight lost.

Should I stop my psoriasis medication if I start Mounjaro? No. You should continue all prescribed psoriasis treatments, including biologics, topical therapies, or phototherapy, unless your dermatologist advises otherwise. Mounjaro complements these treatments by addressing the metabolic inflammation that worsens psoriasis. It does not replace them.

Can Mounjaro make psoriasis worse? There is no evidence that tirzepatide worsens psoriasis. Rapid weight loss can occasionally trigger stress-related flares in some autoimmune conditions, but this is uncommon and typically temporary. If you notice any worsening of your skin while on Mounjaro, contact your prescribing clinician and your dermatologist.

Does Mounjaro help with psoriatic arthritis? The planned TOGETHER-PsA trial is investigating this question. Early data from the psoriasis trials suggest that the anti-inflammatory and weight-reducing effects of tirzepatide should benefit patients with psoriatic arthritis, but dedicated trial results are needed before firm conclusions can be drawn.